OS (Adenocarcinoma):
Key secondary endpoint
met
Nintedanib +
docetaxel
Placebo +
docetaxel
Median, mo
12.6
10.3
HR (95% CI)
0.83
(0.70–0.99)
p value
0.0359
100
80
60
40
20
0
322
302
263
230
203
180
163
149
131
113
96
87
72
59
46
36
25
22
10
336
312
269
219
184
159
139
119
101
88
73
62
55
46
33
29
15
13
7
Probability of survival (%)
52.7%
44.7%
25.7%
19.1%
Time (months)
0
2
4
6
8
10
12
14
16
18
20
22
24
26
28
30
32
34
36
.
Reck M,
et al
.
Lancet Oncol
. 2014;15:143-55.
Number at risk
Nintedanib
Placebo
